ASCO Annual Meeting | Conference

Dr. Bauml on KEYNOTE-055 Study for Patients With HNSCC

June 30th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the preliminary results of the KEYNOTE-055 study, which investigated pembrolizumab (Keytruda) after failure on platinum-based therapy and cetuximab in patients with head and neck squamous cell carcinoma.

Dr. Yurgelun on Susceptibility Gene Mutations in CRC

June 30th 2016

Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma

June 30th 2016

Dr. Spigel on CheckMate-331 Trial for SCLC

June 29th 2016

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.

Dr. Raghav on HER2 Amplification in Patients With CRC

June 24th 2016

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining HER2 gene amplification in patients with metastatic colorectal cancer.

Dr. Charles Ryan Discusses IMAAGEN Trial Update for Prostate Cancer

June 23rd 2016

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer

Dr. Wolchok on Updated CheckMate-067 Results for Melanoma

June 22nd 2016

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, discusses the updated findings from the CheckMate-067 trial, which explored nivolumab (Opdivo) combined with ipilimumab (Yervoy) in treatment-naive patients with advanced melanoma.

Dr. Mehra on KEYNOTE-012 Results of Pembrolizumab in Head and Neck Cancer

June 22nd 2016

Ranee Mehra, MD, chief, Head and Neck Hematology/Oncology, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the KEYNOTE-012 study, which examined the efficacy of pembrolizumab (Keytruda) in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Yardley on HERMIONE-2 Trial for HER2+ Breast Cancer

June 20th 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in patients with anthracycline-naive HER2-positive, locally advanced/metastatic breast cancer who were previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Dr. Ahn on Link Between Tumor Somatic Variants and Chemo Resistance in Biliary Tract Cancer

June 16th 2016

Daniel H. Ahn, MD, assistant professor of Medicine, Mayo Clinic, discusses a next-generation sequencing survey of biliary track cancer to reveal the association between tumor somatic variants and chemotherapy resistance.

Jerome Galon on the Prognostic Value of Immunoscore

June 16th 2016

Jerome Galon, PhD, research director, Institut National de la Santé et de la Recherche Médicale, discusses the prognostic value of the Immunoscore assay and its corresponding validation study, which was presented during the 2016 ASCO Annual Meeting.

Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC

June 15th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability metastatic colorectal cancer.

Dr. Planchard on Dabrafenib/Trametinib Combo in Advanced NSCLC

June 15th 2016

David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib and trametinib in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).

Dr. Rafii on Durvalumab in Patients With Urothelial Bladder Cancer

June 14th 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses a phase I/II dose-escalation study examining the efficacy and safety of the PD-1 antibody durvalumab in patients with metastatic urothelial bladder cancer.

Abiraterone Regimen Demonstrates Safety, Activity in CRPC

June 14th 2016

A combination regimen involving abiraterone acetate (Zytiga) and low-dose prednisone demonstrated a median time to radiographic progression of 41.4 months, as well as a median time to prostate-specific antigen progression of 28.7 months, in men with nonmetastatic castration-resistant prostate cancer.

Dr. Jeffrey Weber on CheckMate-064 Trial for Advanced Melanoma

June 13th 2016

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the design and results of the CheckMate-064 trial, which examined outcomes in patients who received nivolumab (Opdivo) given sequentially with ipilimumab (Yervoy) in patients with advanced melanoma.

T-VEC/Pembrolizumab Combo Shows Early Promise in Advanced Melanoma

June 10th 2016

The combination of the oncolytic virus talimogene laherparepvec (T-VEC) and pembrolizumab (Keytruda) demonstrated evidence of clinical benefit, as well as an acceptable safety profile, in patients with advanced melanoma.

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLC

June 10th 2016

Melissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the phase II BIRCH study, which is examining atezolizumab (Tecentriq) in patients with PD-L1–positive locally advanced or metastatic non–small cell lung cancer (NSCLC).

Pembrolizumab Shows Robust Activity in Head and Neck Cancer

June 10th 2016

Pembrolizumab demonstrated an objective response rate of 18% in data from two clinical trials exploring the PD-1 inhibitor as a treatment for patients with pretreated recurrent or metastatic head and neck squamous cell carcinoma.

Survival Benefit Observed With Olaparib in Ovarian Cancer

June 9th 2016

In patients with platinum-sensitive relapsed serous ovarian cancer, olaparib (Lynparza) was found to significantly increase overall survival when given as maintenance therapy.